Embecta names Devdatt Kurdikar as board chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
embecta names new Chairman of the Board and Lead Independent Director
February 11, 2026 4:10 PM ESTPARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the Board) of embecta has elected Devdatt Dev Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board due to several commitments outside of his service to the Company.
Kurdikar, 57, joined BD... More
